Citations 1
Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months.
Grothey, Axel, Humblet, Yves, Mineur, Laurent , Adenis, Antoine , Lenz, Heinz‐Josef , Goldberg, Richard M. , Wagner, Andrea, Falcone, Alfredo , Bouché, Olivier , Tabernero, Josep , Yoshino, Takayuki , Xu, Lei , Wagner, Andrea, Cutsem, Eric Van
Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e14579-e14579
